Sumitomo Pharma rejects Gotham City Research report on AMCHEPRY, Sumitomo Chemical says
Reuters2026/08/11 23:33- Sumitomo Chemical flagged a statement from subsidiary Sumitomo Pharma disputing a Gotham City Research report published Aug. 7, 2026.
- Sumitomo Pharma rejected the report’s assertions, noting the publisher disclosed short positions that could profit from a share-price decline.
- Sumitomo Pharma defended AMCHEPRY, citing reliability of regulatory submissions, conditional time-limited approval, ongoing Phase 4 study toward full approval.
- The unit also referenced an Aug. 3, 2026 report on financial reporting, warning of possible legal action over misleading information.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Canada keeps rates unchanged for the seventh consecutive time: Tariff wars increase inflation risk, 63% of analysts bet on a shift to rate hikes in the first half of 2027
On September 2, the Bank of Canada held its overnight rate at 2.25% for the seventh consecutive time. However, as the US-Canada tariff war has escalated and inflation risks have intensified, the market has shifted to betting on a rate hike. Governor Macklem warned that trade frictions will threaten the sustainability of the recovery. 63% of analysts expect the Bank of Canada to raise rates in the first half of 2027, while market pricing has shifted from expectations of easing to preparing for tightening in a stagflation scenario.
Warren Buffett and Berkshire’s new CEO pick Alphabet to win AI buildout stakes
Cardano Firm TapTools Scraps Revival NFT Sale After Community Backlash
Crypto prices
More
